About Rockwell Medical, Inc. - Common Stock (RMTI)
Rockwell Medical is a biopharmaceutical company that focuses on developing and providing innovative treatments for patients with chronic kidney disease and end-stage renal disease. The company specializes in therapies aimed at addressing the complications associated with these conditions, particularly iron deficiency anemia. Rockwell Medical is engaged in the research and development of solutions that enhance the quality of life for patients undergoing dialysis and other renal care, aiming to improve patient outcomes through effective medical interventions. Read More
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced preliminary unaudited financial results for the three months and twelve months ended December 31, 2025.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company has added 30 new customers in the western portion of the United States.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Amended and Restated Product Purchase Agreement (the "Amended Agreement") dated September 18, 2023 between the Company and one of the largest dialysis providers in the United States (the "Customer") has been extended through December 31, 2026. As part of the Amended Agreement, product pricing will be increased for the extended term.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joe Dawson to its board of directors. Additionally, Andrea Heslin Smiley has resigned from the Company's board of directors to pursue other endeavors.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and nine months ended September 30, 2025.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Rashad Brown has joined the Company as Vice President, Manufacturing and Supply Chain. Mr. Brown brings more than two decades of leadership experience in manufacturing operations, procurement, warehouse management, and supply chain optimization within regulated healthcare manufacturing environments.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company is exhibiting its hemodialysis concentrates portfolio in Booth #316 at the American Society of Nephrology ("ASN") Kidney Week 2025, which will be held November 6-9 at the George R. Brown Convention Center in Houston, Texas.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Great Place to Work® and Fortune magazine selected Rockwell Medical for the 2025 Fortune Best Workplaces in Manufacturing and ProductionTM List in the small & medium category for the second year in a row.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the third quarter ended September 30, 2025 on Wednesday, November 12, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Heather Hunter was promoted to Chief Operating Officer, and will continue to report to the Company's President and CEO, Dr. Mark Strobeck.
Rockwell Medical narrowed its Q2 2025 loss but missed revenue estimates, posting $16.1M amid customer transition. New contracts aim to stabilize future sales.
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and six months ended June 30, 2025.
